Poul Knoblauch

1.6k total citations · 1 hit paper
17 papers, 1.3k citations indexed

About

Poul Knoblauch is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Poul Knoblauch has authored 17 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 7 papers in Oncology and 4 papers in Hematology. Recurrent topics in Poul Knoblauch's work include Histone Deacetylase Inhibitors Research (11 papers), Protein Degradation and Inhibitors (6 papers) and Multiple Myeloma Research and Treatments (3 papers). Poul Knoblauch is often cited by papers focused on Histone Deacetylase Inhibitors Research (11 papers), Protein Degradation and Inhibitors (6 papers) and Multiple Myeloma Research and Treatments (3 papers). Poul Knoblauch collaborates with scholars based in Denmark, United Kingdom and United States. Poul Knoblauch's co-authors include P. Buhl-Jensen, Chean Eng Ooi, Shanta Chawla, Francine M. Foss, Lee F. Allen, Gajanan Bhat, Jette Tjørnelund, Johann S. de Bono, Laura Vidal and Jeanette K. Doorduijn and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Poul Knoblauch

17 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

2015 386 citations Owen A. O’Connor, Steven M. Horwitz et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Poul Knoblauch

Since Specialization

Citations

This map shows the geographic impact of Poul Knoblauch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Poul Knoblauch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Poul Knoblauch more than expected).

Fields of papers citing papers by Poul Knoblauch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Poul Knoblauch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Poul Knoblauch. The network helps show where Poul Knoblauch may publish in the future.

Co-authorship network of co-authors of Poul Knoblauch

This figure shows the co-authorship network connecting the top 25 collaborators of Poul Knoblauch. A scholar is included among the top collaborators of Poul Knoblauch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Poul Knoblauch. Poul Knoblauch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas 2016 ·Sarcoma ·Joanna Vitfell-Rasmussen, Ian Judson, Akmal Safwat, Robin L. Jones, Philip Rossen, (unknown), Poul Knoblauch, Anders Krarup‐Hansen	27
2	Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study breakdown → 2015 ·Journal of Clinical Oncology ·Owen A. O’Connor, Steven M. Horwitz, Tamás Masszi, Achiel Van Hoof, Peter de Nully Brown, Jeanette K. Doorduijn, Georg Heß, Wojciech Jurczak, Poul Knoblauch, Shanta Chawla, Gajanan Bhat, Mi Rim Choi, Jan Walewski, Kerry J. Savage, Francine M. Foss, Lee F. Allen, Andrei R. Shustov	386
3	A phase I/II clinical trial of belinostat (PXD101) in combination with doxorubicin in patients with soft tissue sarcomas (STS). 2015 ·Journal of Clinical Oncology ·Joanna Vitfell-Rasmussen, (unknown), Akmal Safwat, Philip Rossen, Poul Knoblauch, Robin L. Jones, Ian Judson, Anders Krarup‐Hansen	1
4	Paclitaxel/carboplatin with or without belinostat as empiric first‐line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial 2015 ·Cancer ·John D. Hainsworth, Gedske Daugaard, Thierry Lesimple, G Hübner, F. Anthony Greco, Michael Stahl, Christian Meyer zum Büschenfelde, Djelila Allouache, Nicolas Penel, Poul Knoblauch, Karim Fizazi	37
5	A Phase II trial of Belinostat ( PXD 101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma 2014 ·British Journal of Haematology ·Francine M. Foss, Ranjana H. Advani, Madeleine Duvic, Kenneth B. Hymes, Tanin Intragumtornchai, Arnuparp Lekhakula, Ofer Shpilberg, Adam Lerner, Robert J. Belt, Eric D. Jacobsen, Guy Laurent, Dina Ben‐Yehuda, M. Beylot‐Barry, Uwe Hillen, Poul Knoblauch, Gajanan Bhat, Shanta Chawla, Lee F. Allen, Brad Pohlman	161
6	Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial. 2013 ·Journal of Clinical Oncology ·Owen A. O’Connor, Tamás Masszi, Kerry J. Savage, Lauren Pinter‐Brown, Francine M. Foss, Leslie Popplewell, Amanda F. Cashen, Jeanette K. Doorduijn, Shanta Chawla, Poul Knoblauch, Pier Luigi Zinzani, Peter de Nully Brown, Georg Heß, Achiel Van Hoof, Steven M. Horwitz, Andrei R. Shustov	46
7	Favorable Impact on Mainly Intermediate Cytogenetic Risk AML Can be Predicted by Gene Expression Profiling- Results of a Phase I/II Trial of Belinostat in Combination with Idarubicin in AML 2012 ·Annals of Oncology ·Lars Bullinger, Steen Knudsen, Hervé Dombret, Michael Dennis, Andreas Neubauer, Michael Pfreundschuh, Jean François Rossi, Poul Knoblauch, Jette Tjørnelund, Richard F. Schlenk	1
8	Preliminary Results of An Ongoing Phase I Trial of Oral Belinostat a Novel Histone Deacetylase Inhibitor in Patients with Lymphoid Malignancies, 2011 ·Blood ·Jasmine Zain, Francine M. Foss, Catherine Diefenbach, Daniel P. Petrylak, (unknown), Ellen Neylon, Poul Knoblauch, Owen A. O’Connor	5
9	Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101) 2010 ·Cancer Chemotherapy and Pharmacology ·Nicola Steele, Jane A. Plumb, Laura Vidal, Jette Tjørnelund, Poul Knoblauch, P. Buhl-Jensen, R. Molife, Robert Brown, Johann S. de Bono, T. R. J. Evans	45
10	A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours 2010 ·British Journal of Cancer ·Ulrik Lassen, L. Rhoda Molife, (unknown), (unknown), Laura Vidal, Rajesh Kumar Sinha, Richard T. Penson, P. Buhl-Jensen, Elizabeth Crowley, Jette Tjørnelund, Poul Knoblauch, Johann S. de Bono	72
11	Interim Results of a Phase 1 Trial of An Oral Histone Deacetylase Inhibitor Belinostat In Patients with Lymphoid Malignancies. 2010 ·Blood ·Jasmine Zain, Francine M. Foss, Johann S. de Bono, (unknown), Ellen Neylon, George R. Blumenschein, Ulrik Lassen, Poul Knoblauch, Catherine Diefenbach, Owen A. O’Connor	1
12	A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors 2008 ·Clinical Cancer Research ·Nicola Steele, Jane A. Plumb, Laura Vidal, Jette Tjørnelund, Poul Knoblauch, (unknown), Chean Eng Ooi, P. Buhl-Jensen, Robert Brown, T.R. Jeffry Evans, Johann S. de Bono	211
13	A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia 2008 ·European Journal Of Haematology ·Peter Gimsing, Mads Hansen, Lene Meldgaard Knudsen, Poul Knoblauch, Ib Jarle Christensen, Chean Eng Ooi, P. Buhl-Jensen	140
14	Anthracycline extravasation in breast cancer patients. Effective treatment with dexrazoxane* in three multicenter trials 2008 ·European Journal of Cancer Supplements ·H.T. Mouridsen, Seppo W. Langer, (unknown), (unknown), Jan Buter, Poul Knoblauch, (unknown)	3
15	Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies 2006 ·Annals of Oncology ·H.T. Mouridsen, Seppo W. Langer, Jan Buter, Holger Eidtmann, Giovanni Rosti, Maike de Wit, Poul Knoblauch, (unknown), (unknown), Peter Bjødstrup Jensen, Giuseppe Giaccone	99
16	Iontophoretic in Vitro Release of Antimycotics from Hydrogels 1993 ·Drug Development and Industrial Pharmacy ·F. Moll, Poul Knoblauch	2
17	In vitro pulsatile and continuous transdermal delivery of buserelin by iontophoresis 1993 ·Journal of Controlled Release ·Poul Knoblauch, F. Moll	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact